In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome

In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome

Short QT syndrome variant 1 (SQT1) arises due to gain-of-function mutations to the human Ether-à-go-go-Related Gene (hERG), which encodes the α subunit of channels carrying rapid delayed rectifier potassium current, IKr. In addition to QT interval shortening and ventricular arrhythmias, SQT1 is asso...

Full description

Bibliographic Details
Main Authors: Dominic G. Whittaker, Jules C. Hancox, Henggui Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-01-01
Series:Frontiers in Physiology
Subjects:
arrhythmia
short QT syndrome
atrial fibrillation
hERG
class I anti-arrhythmics
human atria
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2018.01888/full

Internet

https://www.frontiersin.org/article/10.3389/fphys.2018.01888/full

Similar Items